8-K: Neuronetics Completes Acquisition of Greenbrook TMS, Expands Mental Health Treatment Reach

Neuronetics has finalized its acquisition of Greenbrook TMS, creating a larger entity focused on expanding access to mental health treatments.

Summary

• Neuronetics, Inc. has successfully acquired Greenbrook TMS Inc. through a plan of arrangement effective December 9, 2024.
• Each Greenbrook share was converted into 0.01021 of a Neuronetics share.
• Madryn Asset Management converted its debt and interim funding into Greenbrook shares, which were then exchanged for Neuronetics shares.
• Neuronetics secured a $10 million Tranche 3 loan to support the combined operations.
• The company's credit agreement was amended to include new net revenue covenants and extend the Tranche 2 loan availability to January 31, 2026.
• The number of authorized shares of Neuronetics common stock was increased from 200,000,000 to 250,000,000.
• Two new directors, Sasha Cucuz and Avinash Amin, M.D., were appointed to the Neuronetics board, increasing the total number of directors to seven.

Sentiment

Score: 7

Explanation: The document conveys a positive outlook due to the successful acquisition and potential synergies, but also acknowledges risks and challenges associated with integration and achieving profitability.

Positives

• The acquisition combines Neuronetics' technology with Greenbrook's treatment centers, potentially expanding patient access.
• The combined company is expected to have a stronger revenue base and cost synergy opportunities.
• The $10 million Tranche 3 loan provides additional capital for operations.
• The addition of Sasha Cucuz and Avinash Amin, M.D. brings valuable financial and medical expertise to the board.
• The combined company will continue to operate as Neuronetics, Inc., and the Neuronetics Shares will continue to trade on the NASDAQ Global Market under the ticker STIM.

Negatives

• Greenbrook shares will be removed from the OTCQB Market.
• Greenbrook will cease to be a reporting issuer in Canada.
• The company has a history of losses and needs to achieve profitable operations.
• The company is reliant on the sale and use of its NeuroStar Advanced Therapy system to generate revenues.

Risks

• The company faces risks related to integrating the two businesses.
• There are risks associated with achieving or sustaining profitable operations.
• The company is reliant on the sale and use of its NeuroStar Advanced Therapy system to generate revenues.
• The company faces risks related to the availability of coverage and reimbursement from third-party payors.
• There are risks related to physician and patient demand for treatments using the company's products.
• The company faces risks related to developments in competing technologies and therapies.
• The company faces risks related to product defects.
• The company's revenue has been concentrated among a small number of customers.
• The company faces risks related to its ability to obtain and maintain intellectual property protection for its technology.
• The company faces risks related to developments in clinical trials or regulatory review of NeuroStar Advanced Therapy system for additional indications.
• The company faces risks related to developments in regulation in the U.S. and other applicable jurisdictions.
• The company faces risks related to the terms of its credit facility.
• The company faces risks related to its ability to successfully roll-out its Better Me Provider program on the planned timeline.
• The company faces risks related to its self-sustainability and existing cash balances.
• The company faces risks related to its ability to achieve cash flow break-even in the third quarter of 2025.

Future Outlook

The combined company aims to expand patient access to mental health treatments, capitalize on a stronger revenue base and cost synergies, and achieve profitable growth and positive cash flow. The company is targeting cash flow break-even in the third quarter of 2025.

Management Comments

• Keith Sullivan, President and CEO of Neuronetics, stated that the transaction marks a transformative moment in the delivery of mental health therapy.
• Keith Sullivan mentioned that the integration planning teams have made significant progress in mapping out how to bring together the best of both organizations.
• Bill Leonard, President and CEO of Greenbrook, expressed excitement and optimism about the future as a combined company.

Industry Context

This acquisition reflects a trend of consolidation in the mental health treatment industry, where companies are seeking to expand their reach and service offerings. The combination of Neuronetics' technology and Greenbrook's treatment centers positions the combined company to be a significant player in the market.

Comparison to Industry Standards

• Neuronetics' NeuroStar system is a leading TMS treatment for MDD, with over 6.9 million treatments delivered, indicating a strong market position compared to other TMS providers.
• Greenbrook's operation of treatment centers and offering of both TMS and Spravato aligns with the trend of integrated mental health service providers, similar to companies like Acadia Healthcare and Universal Health Services, though these are larger and offer a broader range of services.
• The acquisition is similar to other mergers in the healthcare space where companies combine to achieve economies of scale and expand market reach, such as the merger of Optum and DaVita Medical Group.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders of Greenbrook received Neuronetics shares as part of the acquisition.
• Shareholders of Neuronetics may benefit from the increased scale and potential synergies of the combined company.
• Employees of both companies will be integrated into the new organization.
• Patients may benefit from expanded access to mental health treatments.
• The company's creditors are impacted by the amended credit agreement and new loan.

Next Steps

• The combined company will focus on integrating the two organizations.
• The company will implement strategic initiatives to drive profitable growth and positive cash flow.
• Greenbrook shares will be removed from the OTCQB Market.
• Greenbrook will cease to be a reporting issuer in Canada.
• The company will work towards achieving cash flow break-even in the third quarter of 2025.

Key Dates

Keywords

Neuronetics, Greenbrook TMS, Acquisition, Mental Health, TMS Therapy, Merger, NeuroStar, Depression Treatment, Healthcare, Finance